Los Angeles Capital Management
FDMT icon

Los Angeles Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Los Angeles Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$257K Buy
27,589
+16,309
+145% +$142K ﹤0.01% 1076
2025
Q4 		$128K Hold
11,280
– – ﹤0.01% 1358
2025
Q3 		$98K Hold
11,280
– – ﹤0.01% 1321
2025
Q2 		$41.8K Buy
+11,280
New +$39.7K ﹤0.01% 1317

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Los Angeles Capital Management's FDMT Position: Q1 2026 in Review

Los Angeles Capital Management increased its 4D Molecular Therapeutics (FDMT) stake by 145% in Q1 2026, buying an estimated $142K and bringing the position to 27,589 shares worth $257K. The position accounts for ﹤0.01% of the portfolio, ranked #1076.

Los Angeles Capital Management first reported a position in FDMT in Q2 2025 and has held it in 4 quarters since. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Los Angeles Capital Management held 27,589 shares of 4D Molecular Therapeutics worth $257K as of Q1 2026.
  • Los Angeles Capital Management bought 16,309 4D Molecular Therapeutics shares in Q1 2026, an estimated $142K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1076 holding.
  • Los Angeles Capital Management first reported a position in 4D Molecular Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.